Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study Was Conducted to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HRS-9231 Injection in a Single Dose in Healthy Chinese Subjects

To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of HRS-9231 injection in a single dose in healthy subjects

Inclusion Criteria:

1. Age between 18 to 45 years.
2. Body mass index (BMI) of 19.0 to 28.0 kg/m2 (inclusive).
3. Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written informed consent form (ICF).

Exclusion Criteria:

1. Patients with contraindications for magnetic resonance imaging (MRI) examinations.
2. During the screening period, those whose 12-lead electrocardiogram examination is judged by clinical doctors as abnormal and of clinical significance will be selected.
3. Those with a history of drug abuse, drug use, or positive results in drug abuse screening.
4. Unable to tolerate venipunctures or have a history of fainting needles and blood.
5. People with various urinary disorders (such as frequent urination, difficulty in urination, etc.)